Dr. Reddys Laboratories has signed up Cutis Pharma of USA for active pharmaceutical ingredient (API) supply and joint development agreements. The company will engage in systematic and collaborative research, not only to promote innovative solutions that effectively suffice the needs of patients but also to develop a robust healthcare ecosystem. The partnership with CutisPharma will further enhance and strengthen the R&D portfolio of DRL as well and Cutispharma will advance several R&D programs of its own.
Company Profile : Dr Reddys Laboratories Ltd
Leave a Reply